Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NXP900 · 2 trials · 8 indications
Best response of complete response (CR) or partial response (PR) per RECIST 1.1
Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
Best response of complete response (CR) or partial response (PR) per RECIST 1.1 (or mRECIST 1.1 for subjects with pleural mesothelioma).
Confirmed CR or PR from the first documented response to the date of documented disease progression or death.
The proportion of patients with stable disease (SD), partial response (PR), or complete response (CR).
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Escalating doses of NXP900 given with osimertinib |
| Dose Escalation (Part A) | EXPERIMENTAL | Escalating doses of NXP900 are planned with a starting dose level of 20 mg once per day. |
| Dose Expansion (Part B) | EXPERIMENTAL | Participants will receive the selected dose of NXP900 |
| Name | Type | Description |
|---|---|---|
| NXP900 | DRUG | NXP900 is an orally administered inhibitor of SRC family kinases (SFK) |
| Osimertinib | DRUG | Osimertinib is an orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor |
Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC. 5. Prior treatment with osimertinib as first or second line, as single agent...
NXP900 is an investigational small molecule being studied for the treatment of advanced solid tumors and EGFR mutation positive non-small cell lung cancer. It is currently in Phase 1 clinical development.
NXP900 is a small molecule being developed for oncology indications. Its specific molecular target has not been disclosed in the available clinical trial information.
NXP900 is being developed by Nuvectis Pharma, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol NVCT.
NXP900 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities.
NXP900 is being studied in two Phase 1 trials. One trial, NCT05873686, is evaluating NXP900 in patients with advanced cancers, including solid tumors and non-small cell lung cancer. Another trial, NCT07315113, is studying NXP900 in combination with osimertinib in patients with EGFR-mutated non-small cell lung cancer.
No, NXP900 is not the same as osimertinib. NXP900 is an investigational small molecule being developed by Nuvectis Pharma, while osimertinib is a separate drug used in combination with NXP900 in a clinical trial for EGFR-mutated non-small cell lung cancer.